top of page
Search

Dr Cafer interview on Precision Health & PGX Podcast

Check out the video version of this podcast for a sneak peak of Cafer's Psychopharmacology 2nd edition, in the works for 2025.



Data visualization of medications for EMR by Jason Cafer MD
Iconic Health Medication Iconographs
Duloxetine Cymbalta by Jason Cafer MD
Medication mascots for remembering trade/generic name pairings
Lumateperone Caplyta by Jason Cafer MD
Quetiapine Seroquel by Jason Cafer MD
Quetiapine is effective for mania. "Sera, quit typing and go to sleep!"
Brexpiprazole Rexulti by Jason Cafer MD
Fluvoxamine Luvox by Jason Cafer MD
Fluvoxamine is a fluffer inHibitor
Carbamazepine Tegretol by Jason Cafer MD
Carbamazepine is a shredder inDucer
Induction versus inhibition / Inducers vs Inhibitors CYP450
CYP1A2 interaction
Anything that's an ax decreases levels of anything medication that's a tree
Carbamazepine Tegretol interactions CYP1A2
Carbamazepine decreases levels of CYP1A2 substrates
Interaction between smoking and duloxetine (Cymbalta) by Jason Cafer MD
Hydrocarbons in cigarette smoke decrease levels of duloxetine (not applicable to nicotine vape, gum, or patch)
Interaction between Fluvoxamine (Luvox) and lumateperone (Caplyta) by Jason Cafer MD
Fluvoxamine increases levels of lumateperone
CYP2D6 interactions
Anything that's a pump increases levels of any medication that is a beach ball.
CYP2D6 prodrugs / prodrug interactions
CYP2D6 inhibitors increase 2D6 prodrug substrates (bowling balls), will resultant decrease in efficacy
Inducers of CYP2D6 by Jason Cafer MD
Inducers of CYP2D6 do not exist.
Brexpiprazole (Rexulti) and CYP2D6 normal, ultrarapid, and poor metabolizers / pharmacogenetic testing
Effects of CYP2D6 metabolizer genotype on serum brexpiprazole levels.
CYP2D6 poor metabolizers and tramadol, codeine, and tamoxifen
CYP2D6 poor metabolizers will have diminished efficacy of bowling balls (2D6 prodrugs)
CYP2C19 interactions
Anything that's a watering can will increase levels of any medication that's a flower.
CYP2C19 fluvoxamine and tricyclic antidepressant interactions
Fluvoxamine increases levels of TCAs by inhibition of CYP2C19.
CYP2C19 poor and ultrarapid metabolizers by Jason Cafer MD
Stahl's Essential Psychopharmacology ballicules
The well known ballicule visualization of Stahl's Essential Psychopharmacy, for comparison
Cafer's Psychopharmacology Second Edition - Visualize to Memorize psychiatric medications
Alternate visuals from Cafer's Psychopharmacology 2nd Edition (2025)
Neurotransmitters from Stahl's Essential Psychopharmacology
Neurotransmitters from Stahl's Essential Psychopharmacology, for comparison
Alternative to Stephen Stahl's Essential Psychopharmacology
Neurotransmitters are ballicules in Cafer's Psychopharmacology 2nd Edition (2025). The ring around epinephrine signifies poor penetrance across the blood-brain barrier.
Alternative to Stahl's Essential Psychopharmacology
"Anti-neurotransmitter" visuals from Cafer's Psychopharmacology 2nd Edition (2025)
Bioengineering of psychotropic medications by Jason Cafer MD including mirtazapine (Remeron)
How to bioengineer a psychotropic medication from "anti-neurotransmitters"
Alternative to Stahl's essential psychopharmacology for pharmacokinetic interactions
CaferMed ballicules include visuals for pharmacokinetic drug interactions. Also note that fluvoxamine is a sigma-1 agonist which may confer neuroprotection, anxiolytic effects, and amelioration of psychotic depression. Sertraline is the opposite as a sigma-1 inverse agonist which may have anti-cancer effects but there is theoretical concern for neurotoxicity.
Stephen Stahl's Essential Psychopharmacology alternative
Pharmacokinetic elements of ballicules
CYP inhibitor and substrate explanation
InHibitors increase levels of sensitive substrates for a particular enzyme.
CYP inducers and substrates
InDucers decrease substrate levels
Medications that do not interact with other drugs
Overlapping elements between ballicules and interaction avatars. The hole in the top of the glass box signifies the possibility of some pharmacokinetic interaction(s) that are unlikely to be clinically relevant or that are beyond the scope of the visual mnemonic framework.



Copyright 2024, CaferMed


Comments

bottom of page